Tofogliflozin - 97%, high purity , CAS No.903565-83-3, Inhibitor of Sodium/glucose cotransporter 1;Inhibitor of Sodium/glucose cotransporter 2

Item Number
T178116
Grouped product items
SKUSizeAvailabilityPrice Qty
T178116-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,051.90

Basic Description

SynonymsDTXSID90238097 | R-7201 | GTPL9395 | RO4998452 | RO-4998452 | AC-31468 | C6H18N3OP | NCGC00485920-01 | CSG 452 | deberza | compound 16d [PMID: 22889351] | NCGC00257160-01 | Tofogliflozin [INN] | A836961 | BDBM50396779 | Tofogliflozin anhydrous | UNII-5542
Specifications & PurityMoligand™, ≥97%
Storage TempRoom temperature
Shipped InNormal
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of Sodium/glucose cotransporter 1;Inhibitor of Sodium/glucose cotransporter 2

AI Insight

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name (3S,3'R,4'S,5'S,6'R)-5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol
INCHI InChI=1S/C22H26O6/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22+/m1/s1
InChi Key VWVKUNOPTJGDOB-BDHVOXNPSA-N
Canonical SMILES CCC1=CC=C(C=C1)CC2=CC3=C(COC34C(C(C(C(O4)CO)O)O)O)C=C2
Isomeric SMILES CCC1=CC=C(C=C1)CC2=CC3=C(CO[C@@]34[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C=C2
PubChem CID 46908929
Molecular Weight 386.444

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Related Documents

Reviews

Customer Reviews

References

1. Ohtake Y, Sato T, Kobayashi T, Nishimoto M, Taka N, Takano K, Yamamoto K, Ohmori M, Yamaguchi M, Takami K et al..  (2012)  Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes..  J Med Chem,  55  (17): (7828-40).  [PMID:22889351] [10.1021/op500134e]
2. Faillie JL.  (2017)  Pharmacological aspects of the safety of gliflozins..  Pharmacol Res,  118  (13): (71-81).  [PMID:27389050] [10.1021/op500134e]
3. Poole RM, Prossler JE.  (2014)  Tofogliflozin: first global approval..  Drugs,  74  (8): (939-44).  [PMID:24848755] [10.1021/op500134e]

Solution Calculators